![Giacomo Chiesi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Giacomo Chiesi is the founder of Chiesi SA (Belgium) in 2010, Chiesi Pharma AB in 1935, and CHIESI Farmaceutici SpA in 1935 where he is currently the Director & Head-Global Rare Diseases.
He is currently the Director at Sentien Biotechnologies, Inc. and the Managing Partner at Chiesi Ventures, Inc. He was also a former Board Member at Glycomine, Inc.
Giacomo Chiesi active positions
Companies | Position | Start |
---|---|---|
CHIESI Farmaceutici SpA
![]() CHIESI Farmaceutici SpA Pharmaceuticals: MajorHealth Technology Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy. | Founder | 1934-12-31 |
Sentien Biotechnologies, Inc.
![]() Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | Director/Board Member | - |
Chiesi Ventures, Inc.
![]() Chiesi Ventures, Inc. Investment ManagersFinance Chiesi Ventures, Inc.(Chiesi Ventures) is an venture capital firm founded in 2014. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 2013-12-31 |
Former positions of Giacomo Chiesi
Companies | Position | End |
---|---|---|
Chiesi SA (Belgium)
![]() Chiesi SA (Belgium) Pharmaceuticals: MajorHealth Technology Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi. | Founder | - |
Chiesi Pharma AB
![]() Chiesi Pharma AB BiotechnologyHealth Technology Chiesi Pharma AB is a private company that engages in research and development, manufacturing, and selling of medicines. Chiesi Pharma AB is based in Stockholm, Sweden. It was founded in 1935 by Giacomo Chiesi, and the CEO is Olav Henrik Fromm. | Founder | - |
Glycomine, Inc.
![]() Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 6 |
---|---|
CHIESI Farmaceutici SpA
![]() CHIESI Farmaceutici SpA Pharmaceuticals: MajorHealth Technology Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy. | Health Technology |
Chiesi SA (Belgium)
![]() Chiesi SA (Belgium) Pharmaceuticals: MajorHealth Technology Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi. | Health Technology |
Chiesi Ventures, Inc.
![]() Chiesi Ventures, Inc. Investment ManagersFinance Chiesi Ventures, Inc.(Chiesi Ventures) is an venture capital firm founded in 2014. The firm is headquartered in Boston, Massachusetts. | Finance |
Glycomine, Inc.
![]() Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
Chiesi Pharma AB
![]() Chiesi Pharma AB BiotechnologyHealth Technology Chiesi Pharma AB is a private company that engages in research and development, manufacturing, and selling of medicines. Chiesi Pharma AB is based in Stockholm, Sweden. It was founded in 1935 by Giacomo Chiesi, and the CEO is Olav Henrik Fromm. | Health Technology |
Sentien Biotechnologies, Inc.
![]() Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Giacomo Chiesi